Roles of LncRNAs in Regulating Mitochondrial Dysfunction in Septic Cardiomyopathy

Liu, Shuang; Wang, Chong

doi:10.3389/fimmu.2021.802085

Cited by 15 publications

(11 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have found that once sepsis is combined with myocardial damage, it can aggravate the evolution of the disease, increase the risk of multiple organ failure and death, and seriously affect the prognosis of the patient. It was shown that about 40% to 50% of sepsis patients have cardiac insufficiency, and sepsis-induced myocardial dysfunction (SIMD) is an increasingly recognized form of transient cardiac dysfunction characterized by decreased ventricular systolic and diastolic function, and/or reduced response to volume resuscitation ( Zhang et al., 2020 ; Liu and Chong, 2021 ). A historical cohort study of 388 patients hospitalized with severe sepsis or septic shock demonstrated that even isolated right ventricular dysfunction is associated with worse long-term survival ( Vallabhajosyula et al., 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Association Between Gut Dysbiosis and Sepsis-Induced Myocardial Dysfunction in Patients With Sepsis or Septic Shock

Chen

Zhang

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

ObjectiveSepsis-induced myocardial dysfunction (SIMD) seriously affects the evolution and prognosis of the sepsis patient. The gut microbiota has been confirmed to play an important role in sepsis or cardiovascular diseases, but the changes and roles of the gut microbiota in SIMD have not been reported yet. This study aims to assess the compositions of the gut microbiota in sepsis or septic patients with or without myocardial injury and to find the relationship between the gut microbiota and SIMD.MethodsThe prospective, observational, and 1:1 matched case–control study was conducted to observe gut microbiota profiles from patients with SIMD (n = 18) and matched non-SIMD (NSIMD) patients (n = 18) by 16S rRNA gene sequencing. Then the relationship between the relative abundance of microbial taxa and clinical indicators and clinical outcomes related to SIMD was analyzed. The receiver operating characteristic (ROC) curves were used to evaluate the predictive efficiencies of the varied gut microbiota to SIMD.ResultsSIMD was associated with poor outcomes in sepsis patients. The beta-diversity of the gut microbiota was significantly different between the SIMD patients and NSIMD subjects. The gut microbiota profiles in different levels significantly differed between the two groups. Additionally, the abundance of some microbes (Klebsiella variicola, Enterobacteriaceae, and Bacteroides vulgatus) was correlated with clinical indicators and clinical outcomes. Notably, ROC analysis indicated that K. variicola may be a potential biomarker of SIMD.ConclusionOur study indicates that SIMD patients may have a particular gut microbiota signature and that the gut microbiota might be a potential diagnostic marker for evaluating the risk of developing SIMD.

show abstract

Section: Introductionmentioning

confidence: 99%

Association Between Gut Dysbiosis and Sepsis-Induced Myocardial Dysfunction in Patients With Sepsis or Septic Shock

Chen

Zhang

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Septic cardiomyopathy, also known as sepsis-induced myocardial dysfunction, was rst described in 1984 as a reversible myocardial depression with an initial decrease in left ventricular ejection fraction accompanied by a decrease in cardiac index [6] . However, with the continuous updating of relevant studies, we found that not only left ventricular systolic dysfunction exists in septic cardiomyopathy, but also left ventricular diastolic dysfunction and right ventricular systolic dysfunction [7] . Although septic cardiomyopathy has not been clearly de ned, most scholars agree that septic cardiomyopathy is a reversible myocardial depression characterized by left ventricular dilatation and biventricular systolic and/or diastolic dysfunction, and the recovery period is 7-10 days [8] .…”

Section: Introductionmentioning

confidence: 91%

Clinical study on the relationship between gut microbiota dysbiosis and iron metabolism and septic cardiomyopathy

Wang

Lin

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Septic cardiomyopathy is a common complication of sepsis and is characterized by ventricular systolic and/or diastolic dysfunction and reduced ejection fraction. Studies have demonstrated the role of gut microbiota and iron metabolism in sepsis and cardiovascular disease, but few studies have reported on the changes and role of gut microbiota and iron metabolism in septic cardiomyopathy. The aim of this study was to explore the changes and correlation of gut microbiota and iron metabolism in septic cardiomyopathy and to provide new directions for early diagnosis of septic cardiomyopathy. Methods: This study was a Single-center, prospective, observational study. Patients with sepsis who were admitted to the critical care medicine department of Subei People's Hospital between February 2022 and September 2022 were selected. Echocardiography was performed within 72 hours of the patient's admission to the Intensive care unit. Patients were divided into septic cardiomyopathy group and non-septic cardiomyopathy group according to the grouping criteria. Blood and stool specimens were collected from patients included in the study on days 1, 3 and 7 of enrollment. The blood specimens for testing of iron metabolism levels. The stool specimens were for 16S rDNA sequencing to detect intestinal microbiota diversity. The basic vital signs and clinical data of the patient were recorded. To compare the gut microbiota diversity, iron metabolism level, 28-day morbidity and mortality rate, length of ICU stay, and total length of stay in the two groups. Results: A total of 48 patients were enrolled during the study period, including 23 patients in the septic cardiomyopathy group and 25 patients in the non-septic cardiomyopathy group. Analysis of iron metabolism levels in the two groups showed that there was a statistical difference in serum ferritin levels between the two groups on day 1 and day 3 of enrollment (P < 0.05), and that ferritin levels were higher in the septic cardiomyopathy group than in the non-septic cardiomyopathy group. Other iron metabolism levels including serum iron, serum transferring, transferrin saturation, and total iron binding capacity on days 1, 3, and 7 were not statistically significant (P > 0.05). Analysis of the richness and diversity of the gut microbiota in the two groups showed that the ACE index and Chao1 index were statistically different between the two groups (P < 0.01), while the Shannon index and Simpson index were not statistically different (P > 0.05). Beta diversity of gut microbiota was analyzed in both groups and PCoA analysis showed a significant difference (P < 0.01). We compared the composition of the gut microbiota at different taxonomic levels in the two groups of patients, and at the phylum level, the abundance of Actinobacteria (P=0.018) and unidentified_Bacteria (P=0.024) was lower in the septic cardiomyopathy group. At the family level, the abundance of Aeromonadaceae was lower in the septic cardiomyopathy group (P=0.023). At the genus level, Citrobacter was more abundant in septic cardiomyopathy (P=0.007). At the species level, Bacteroides_nordii (P=0.037) and [Clostridium]_celerecrescens (P=0.026) were more abundant in septic cardiomyopathy. By Linear discriminant analysis Effect size (LEfSe) analysis, we identified Enterobacter and Klebsiella_quasipneumoniae as possible gut microbe specific for septic cardiomyopathy (LDA score=4.2747, P=0.003). Using Spearman's rank correlation analysis of clinical indicators and gut microbiota, we found that Bacteroides_thetaiotaomicron was positively correlated with B-type natriuretic peptide, serum iron, and transferrin saturation (P < 0.05). Bacteroides_fragilis was negatively correlated with cardiac Troponin I, transferrin, total iron binding capacity were negatively correlated (P < 0.05). Prevotella_disiens and Prevotella_timonensis were negatively correlated with ferritin (P < 0.05). Conclusion: Our study suggests that ferritin may have predictive value for early identification of septic cardiomyopathy, while Enterobacteriaceae may be the gut microbiota specific to septic cardiomyopathy. Furthermore, alterations in gut microbiota diversity may influence changes in iron metabolism and ultimately induce the development of septic cardiomyopathy, and larger studies are needed to validate this in the future. Trial registration: The trial completed registration at the China Clinical Trials Registry (registration number ChiCTR2200056572) on 8 February 2022, and the study was conducted in strict accordance with the registration information.

show abstract

“…Sj-Cys could alleviate excessive inflammation and protect against sepsis-induced cardiac dysfunction in a mouse model of sepsis-induced myocardial injury. [10] Similarly, melatonin has been investigated as a potential treatment, [18,37,38] as evidenced in a study where a mouse model showed that melatonin is effective in attenuating septic myocardial injury. [38] Furthermore, gene therapy is promising as a possible therapeutic agent for septic cardiomyopathy and may reduce the inflammation associated with sepsis, improving cardiac function.…”

Section: Potential Treatment Optionsmentioning

confidence: 99%

Clinical implications of septic cardiomyopathy: A narrative review

Hiraiwa,

Kasugai,

Okumura

et al. 2024

Medicine

View full text Add to dashboard Cite

Sepsis is caused by the body’s dysregulated response to infection, which can lead to multiorgan injury and death. Patients with sepsis may develop acute cardiac dysfunction, termed septic cardiomyopathy, which is a global but reversible dysfunction of both sides of the heart. This narrative review discusses the mechanistic changes in the heart during septic cardiomyopathy, its diagnosis, existing treatment options regarding severity and course, and emerging treatment approaches. Although no standardized definition for septic cardiomyopathy exists, it is described as a reversible myocardial dysfunction that typically resolves within 7 to 10 days. Septic cardiomyopathy is often diagnosed based on electrocardiography, cardiac magnetic resonance imaging, biomarkers, and direct invasive and noninvasive measures of cardiac output. Presently, the treatment of septic cardiomyopathy is similar to that of sepsis, primarily focusing on acute interventions. Treatments for cardiomyopathy often include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics. However, because of profound hypotension in sepsis, many cardiomyopathy treatments are contraindicated in patients with septic cardiomyopathy. Substantial efforts have been made to study the pathophysiological mechanisms and diagnostic options; however, the lack of a uniform definition for septic cardiomyopathy is challenging for physicians when considering treatments. Another challenge for physicians is that the treatment for septic cardiomyopathy has only focused on acute intervention, whereas the treatment for other cardiomyopathies has been provided on a long-term basis. A better understanding of the underlying mechanisms of septic cardiomyopathy may contribute to the development of a unified definition of the condition and novel treatment options.

show abstract

Roles of LncRNAs in Regulating Mitochondrial Dysfunction in Septic Cardiomyopathy

Cited by 15 publications

References 103 publications

Association Between Gut Dysbiosis and Sepsis-Induced Myocardial Dysfunction in Patients With Sepsis or Septic Shock

Association Between Gut Dysbiosis and Sepsis-Induced Myocardial Dysfunction in Patients With Sepsis or Septic Shock

Clinical study on the relationship between gut microbiota dysbiosis and iron metabolism and septic cardiomyopathy

Clinical implications of septic cardiomyopathy: A narrative review

Contact Info

Product

Resources

About